SOD2 and cardiomyopathy: Taking all these findings together, the present study revealed that APS therapy could improve cardiomyopathy in STZ-induced diabetic mice and heterozygous SOD2+/- knockout mice with reduced cardiac apoptosis/necrosis and enhanced cardiac proliferation, leading to a marked recovery of ventricular function and protection of myocardial ultrastructure.